Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ EDC3 Polyclonal Antibody
Rabbit Polyclonal Antibody
Supplier: Invitrogen™ PA584710
Description
Immunogen sequence: IDTYERRSGT RSRGIPNERP TRYRHDENIL ESEPIVYRRI IVPHNVSKEF CTDSGLVVPS ISYELHKKLL SVAEKHGLTL ERRLE.
This gene encodes a protein that is important in mRNA degradation. The encoded protein is a component of a decapping complex that promotes efficient removal of the monomethylguanosine (m7G) cap from mRNAs, as part of the 5' to 3' mRNA decay pathway. Mutations in this gene have been identified in human patients with an autosomal recessive form of intellectual disability.
Specifications
EDC3 | |
Polyclonal | |
Unconjugated | |
Edc3 | |
AA517853; EDC3; enhancer of mRNA decapping 3; enhancer of mRNA decapping 3 homolog; enhancer of mRNA decapping 3 homolog (S. cerevisiae); enhancer of mRNA-decapping protein 3; hYjeF_N2; hYjeF_N2-15q23; hypothetical protein FLJ21128; hypothetical protein LOC504054; im:7151288; Lsm16; LSM16 homolog; LSM16 homolog (EDC3, S. cerevisiae); LSM16 protein homolog; MRT50; PP844; RGD1306898; wu:fb82d07; Yjdc; yjeF domain containing; yjeF domain-containing protein 1; YjeF N-terminal domain-containing protein 2; yjeF_N2; YJEFN2; zgc:112006 | |
Rabbit | |
Antigen affinity chromatography | |
RUO | |
80153 | |
Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles. | |
Liquid |
Western Blot, Immunocytochemistry, Western Blot | |
0.1 mg/mL | |
PBS with 40% glycerol and 0.02% sodium azide; pH 7.2 | |
Q96F86 | |
Edc3 | |
Recombinant protein corresponding to Human EDC3. Recombinant protein control fragment (Product #RP-105383). | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG |
Safety and Handling
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction